Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The selection of the registry's participants will be based on an exhaustive request of all apheresis centers distributed in the French territory.
Patients treated with Plerixafor for autologous transplantation between November 2011 and November 2012
Patients who have been informed and who have given their written consent for the access to their medical file
Patients already included in a Plerixafor ongoing clinical trial.